Author Correction: Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity.

Autor: McMillin DW; Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Department of Medical Oncology, Harvard Medical School, Boston, Massachusetts, USA.; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA., Delmore J; Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Department of Medical Oncology, Harvard Medical School, Boston, Massachusetts, USA.; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA., Weisberg E; Department of Medical Oncology, Harvard Medical School, Boston, Massachusetts, USA.; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA., Negri JM; Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Department of Medical Oncology, Harvard Medical School, Boston, Massachusetts, USA.; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA., Geer CD; Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Department of Medical Oncology, Harvard Medical School, Boston, Massachusetts, USA.; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA., Klippel S; Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Department of Medical Oncology, Harvard Medical School, Boston, Massachusetts, USA.; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA., Mitsiades N; Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Department of Medical Oncology, Harvard Medical School, Boston, Massachusetts, USA., Schlossman RL; Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Department of Medical Oncology, Harvard Medical School, Boston, Massachusetts, USA.; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA., Munshi NC; Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Department of Medical Oncology, Harvard Medical School, Boston, Massachusetts, USA.; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.; Boston VA Healthcare System, Boston, Massachusetts, USA., Kung AL; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Griffin JD; Department of Medical Oncology, Harvard Medical School, Boston, Massachusetts, USA.; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA., Richardson PG; Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Department of Medical Oncology, Harvard Medical School, Boston, Massachusetts, USA.; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA., Anderson KC; Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Department of Medical Oncology, Harvard Medical School, Boston, Massachusetts, USA.; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA., Mitsiades CS; Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, Massachusetts, USA. constantine_mitsiades@dfci.harvard.edu.; Department of Medical Oncology, Harvard Medical School, Boston, Massachusetts, USA. constantine_mitsiades@dfci.harvard.edu.; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA. constantine_mitsiades@dfci.harvard.edu.

Publikováno v: Nature medicine [Nat Med] 2024 Apr; Vol. 30 (4), pp. 1214.

Accessory cells of the microenvironment protect multiple myeloma from T-cell cytotoxicity through cell adhesion-mediated immune resistance.

Autor: de Haart SJ; Authors' Affiliations: Departments of Clinical Chemistry and Hematology, Hematology, Pathology, Cell biology, Immunology, University Medical Center Utrecht, Utrecht; Xpand Biotechnology BV, Bilthoven, the Netherlands; and Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, Massachusetts., van de Donk NW, Minnema MC, Huang JH, Aarts-Riemens T, Bovenschen N, Yuan H, Groen RW, McMillin DW, Jakubikova J, Lokhorst HM, Martens AC, Mitsiades CS, Mutis T

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2013 Oct 15; Vol. 19 (20), pp. 5591-601. Date of Electronic Publication: 2013 Sep 04.

High-throughput approaches to discover novel immunomodulatory agents for cancer.

Autor: McMillin DW; Department of Medical Oncology; Dana-Farber Cancer Institute; Boston, MA USA ; Department of Medicine; Harvard Medical School; Boston, MA USA., Mitsiades CS

Publikováno v: Oncoimmunology [Oncoimmunology] 2012 Nov 01; Vol. 1 (8), pp. 1406-1408.

Adenosine A2A and beta-2 adrenergic receptor agonists: novel selective and synergistic multiple myeloma targets discovered through systematic combination screening.

Autor: Rickles RJ; Zalicus Inc., Cambridge, Massachusetts 02142, USA. rrickles@zalicus.com, Tam WF, Giordano TP 3rd, Pierce LT, Farwell M, McMillin DW, Necheva A, Crowe D, Chen M, Avery W, Kansra V, Nawrocki ST, Carew JS, Giles FJ, Mitsiades CS, Borisy AA, Anderson KC, Lee MS

Publikováno v: Molecular cancer therapeutics [Mol Cancer Ther] 2012 Jul; Vol. 11 (7), pp. 1432-42. Date of Electronic Publication: 2012 Apr 03.

Compartment-Specific Bioluminescence Imaging platform for the high-throughput evaluation of antitumor immune function.

Autor: McMillin DW; Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Delmore J, Negri JM, Vanneman M, Koyama S, Schlossman RL, Munshi NC, Laubach J, Richardson PG, Dranoff G, Anderson KC, Mitsiades CS

Publikováno v: Blood [Blood] 2012 Apr 12; Vol. 119 (15), pp. e131-8. Date of Electronic Publication: 2012 Jan 30.